Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Vornado Realty Trust Q4 FFO Down - Quick Facts

RELATED NEWS
Trade VNO now with 

Vornado Realty Trust (VNO: Quote) reported that its fourth-quarter funds from operations attributable to common shareholders plus assumed conversions or FFO was $280.4 million or $1.46 per share, down from $432.9 million or $2.27 per share, for the prior year's quarter.

Adjusting FFO, quarter was $220.1 million or $1.15 and $218.3 million, or $1.15 per share last year.

Revenues for the quarter rose to $741.82 million from $702.84 million in the prior year quarter.

Net income attributable to common shareholders for the quarter was $69.5 million, or $0.37 per share, compared to $243.4 million, or $1.31 per share, for the quarter ended December 31, 2010.

Net income for the quarters ended December 31, 2011 and 2010 includes $1.9 million and $62.7 million, respectively, of net gains on sale of real estate, and $28.8 million and $104.0 million, respectively, of real estate impairment losses.

Adjusting net income attributable to common shareholders for the quarter was $34.5 million or $0.18, down from $69.9 million, or and $0.40 per share in the year ago quarter.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.24 per share on revenues of $666.64 million for the quarter. Analysts' estimates typically exclude special items.

Register
To receive FREE breaking news email alerts for Vornado Realty Trust and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.